K-Stemcell’s Arthritis Cell Therapy Set For Phase III In Korea
This article was originally published in PharmAsia News
Executive Summary
In another positive sign for South Korea’s stem cell space, one of the government’s priorities in the biotech sector, K-Stemcell will begin late-stage clinical trials with JOINTSTEM, an autologus adipose-derived stem cell therapy for degenerative arthritis, with a goal of commercialization in 2018.